IL312187A - Methods for treating prurigo nodularis by administering an IL-4R antagonist - Google Patents

Methods for treating prurigo nodularis by administering an IL-4R antagonist

Info

Publication number
IL312187A
IL312187A IL312187A IL31218724A IL312187A IL 312187 A IL312187 A IL 312187A IL 312187 A IL312187 A IL 312187A IL 31218724 A IL31218724 A IL 31218724A IL 312187 A IL312187 A IL 312187A
Authority
IL
Israel
Prior art keywords
antagonist
administering
methods
prurigo nodularis
treating prurigo
Prior art date
Application number
IL312187A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of IL312187A publication Critical patent/IL312187A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL312187A 2021-10-20 2022-10-19 Methods for treating prurigo nodularis by administering an IL-4R antagonist IL312187A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163257876P 2021-10-20 2021-10-20
US202263300492P 2022-01-18 2022-01-18
EP22315048 2022-03-04
PCT/US2022/078341 WO2023069976A1 (en) 2021-10-20 2022-10-19 Methods for treating prurigo nodularis by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
IL312187A true IL312187A (en) 2024-06-01

Family

ID=84329583

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312187A IL312187A (en) 2021-10-20 2022-10-19 Methods for treating prurigo nodularis by administering an IL-4R antagonist

Country Status (10)

Country Link
US (1) US20230183362A1 (https=)
EP (1) EP4419557A1 (https=)
JP (1) JP2024539148A (https=)
KR (1) KR20240099290A (https=)
CN (1) CN119137149A (https=)
AU (1) AU2022369296A1 (https=)
CA (1) CA3235380A1 (https=)
IL (1) IL312187A (https=)
MX (1) MX2024004762A (https=)
WO (1) WO2023069976A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
IL293487A (en) * 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
US20230374144A1 (en) 2020-09-10 2023-11-23 Staidson (Beijing) Biopharmaceutical Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof

Also Published As

Publication number Publication date
US20230183362A1 (en) 2023-06-15
MX2024004762A (es) 2024-05-08
JP2024539148A (ja) 2024-10-28
WO2023069976A1 (en) 2023-04-27
EP4419557A1 (en) 2024-08-28
CN119137149A (zh) 2024-12-13
AU2022369296A1 (en) 2024-05-30
CA3235380A1 (en) 2023-04-27
KR20240099290A (ko) 2024-06-28

Similar Documents

Publication Publication Date Title
IL289930A (en) Methods for treating atopic dermatitis using an IL-4R antagonist
IL274134A (en) Methods of treating or preventing asthma by administering an IL-4R agonist
SG11202113312VA (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
IL312187A (en) Methods for treating prurigo nodularis by administering an IL-4R antagonist
PL3506931T3 (pl) Sposoby zapobiegania lub leczenia alergii poprzez podawanie antagonisty il-4r
SG11202009371WA (en) Methods for treating atopic dermatitis by administering an il-4r inhibitor
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
IL289731A (en) Methods for treating or preventing asthma by administering an antagonist to il-4r
SG11201509625PA (en) Methods for treating nasal polyposis by administering an il-4r antagonist
IL291452A (en) Dosage forms for tyk2 inhibitors
MY163953A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
IL310962A (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
IL287275A (en) Methods of treating or preventing asthma by administering an IL-33 agonist
MX2020008569A (es) Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.
IL320362A (en) Methods for treating hand and foot skin infections by administering an IL-4R antagonist
PL3953393T3 (pl) Połączenie farmaceutyczne antagonisty ep4 i inhibitorów punktów kontrolnych układu odpornościowego do leczenia nowotworów
IL307488A (en) Treatments for prurigo nodularis
IL293544A (en) Methods for treating COPD by giving IL-33 antagonist
MX2019004804A (es) Tratamiento para el prurigo nodula.
HK40114753A (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
PH12017501881A1 (en) Methods for treating cancer
PT4333840T (pt) Inibidores da via jak1 para o tratamento de prurigo nodularis
IL318016A (en) Methods for treating eosinophilic esophagitis in children by administering an IL-4R antagonist
LT3010539T (lt) Nazalinės polipozės gydymo būdai, skiriant il-4r antagonistą
IL319323A (en) Treatments for prurigo nodularis